Stoke Therapeutics Comes Out of Seed Mode With $40M and Ex-Sarepta CEO at Its Helm Post author:Sam Post published:January 3, 2018 Post category:BioPharma The Series A round was entirely funded by founding investor Apple Tree Partners. Source: BioSpace You Might Also Like How to Write the Best Cover Letter for a Research Scientist Job February 15, 2017 Reported Side Effects Raise Concerns for Regeneron’s Eylea February 21, 2018 Insmed Rockets as Lung Drug Wows in Late-Stage Study September 4, 2017
